IAS–USA Virtual Update on HIV: Antiretroviral Therapy, New ART Drugs and Strategies, and the Intersection of COVID-19 and HIV

IAS–USA Virtual Update on HIV: Antiretroviral Therapy, New ART Drugs and Strategies, and the Intersection of COVID-19 and HIV

Registration Details

  • Preregistration: $35.00 (USD)
  • Preregistration ends: Thursday, July 30, 2020


Constance A. Benson, MD
University of California San Diego
Susan P. Buchbinder, MD
University of California San Francisco
Joseph J. Eron, Jr, MD
University of North Carolina at Chapel Hill
Sally Hodder, MD
West Virginia University
Babafemi O. Taiwo, MBBS
Northwestern University
Paul A. Volberding, MD
University of California San Francisco

July 30, 2020

10:00 AM to 2:30 PM CT


If you registered for the course before Wednesday, July 29, an email from IAS-USA Support (a no-reply Zoom address) with your personal link to access the virtual course was sent to you today at 2:00 PM Central Time (12:00 PM PT, 1:00 PM MT, 3:00 PM ET). You will also receive an email reminder with this link an hour before the virtual course. Please check your spam folder if you did not receive an email.

If you registered after Tuesday, instructions on how to join are included in your registration confirmation message. Please be sure to click on the link provided in the email to get your personal link to access the virtual course.


Program Description

This new virtual CME course from the IAS–USA combines planned presentations from the postponed courses, including the Chicago HIV update course. We have shortened the program and narrowed down the topics to the key issues on which most of you are likely focusing, as we know it is difficult for you to dedicate an entire day to participate in a virtual course during this time. We will cover other topics related to comorbidities, issues in aging, and so on in our COW webinar programming, which you can access live or on demand.

Although scheduled to accommodate HIV clinicians in the Central time zone, the course is open to all.

We are doing our best to adapt during this uncertain time and provide you with timely updates on key issues in formats you can easily access. We appreciate any feedback you have for us, and we thank you for your patience.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in HIV medicine. This course will address the implications of new information on strategies for clinical management. Information will be presented virtually through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Describe the most current data on currently available new antiretroviral drugs and approaches
  • Identify situations in which the choice of antiretroviral regimens should consider particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Initiate and monitor HIV prevention intervention strategies, including the use of preexposure prophylaxis (PrEP), in individuals at risk for HIV infection
  • Describe the status of research into treatment and the current best understanding of the impact of COVID-19 on HIV
  • Identify individuals with chronic opioid dependency and develop treatment strategies for the management of these patients with opioid substitution therapy

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”


We will be processing full refunds for everyone who registered for one of the IAS–USA 2020 regional spring HIV courses. Earlier, we had offered the option of transferring registrations to a later live course, but the ongoing COVID-19 pandemic has made it so we do not know when this will be.

Thus, our decision to refund all spring course registration fees. Processing these refunds might take several weeks, so we appreciate your patience.

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 4.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 4.25 contact hours (0.425 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-20-113-L03-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Food and beverages at IAS–USA events are purchased with registration fees, not with grant support money. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare


Janssen Therapeutics

Physician Payment Sunshine Act (“Sunshine Act” or “Open Payment”)

In 2014, the Physician Payment Sunshine Act (“Sunshine Act” or “Open Payments”), a provision of the Affordable Care Act, was developed. According to the Centers for Medicare and Medicaid Services (CMS): “Open Payments is a national disclosure program that promotes transparency by publishing the financial relationships between the medical industry and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS.” Until recently, CME activities that receive commercial support have been exempt from reporting payments for goods such as hosted meals. Attendee registration fees are used for all food and beverage expenses provided by IAS–USA at the activity.